{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=alum+adjuvant",
    "query": {
      "intervention": "alum adjuvant"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 163,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=alum+adjuvant&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T07:59:10.092Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02475278",
      "title": "Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Norovirus",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "NoV GI.1/GII.4 Bivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2015-02-26",
      "completion_date": "2015-09-09",
      "has_results": true,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475278"
    },
    {
      "nct_id": "NCT05781542",
      "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "sD-NP-GT8 DNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 DNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2023-04-10",
      "completion_date": "2025-04-14",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05781542"
    },
    {
      "nct_id": "NCT00679302",
      "title": "Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Skin Diseases, Infectious"
      ],
      "interventions": [
        {
          "name": "Trimethoprim-sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 161,
      "start_date": "2006-07",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-04",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679302"
    },
    {
      "nct_id": "NCT03455309",
      "title": "Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcus Aureus"
      ],
      "interventions": [
        {
          "name": "NDV-3A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NovaDigm Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "17 Years to 35 Years · Male only"
      },
      "enrollment_count": 382,
      "start_date": "2018-01-30",
      "completion_date": "2019-10-15",
      "has_results": false,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 1,
      "location_summary": "Fort Benning, Georgia",
      "locations": [
        {
          "city": "Fort Benning",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03455309"
    },
    {
      "nct_id": "NCT00001096",
      "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS-21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": null,
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001096"
    },
    {
      "nct_id": "NCT04032093",
      "title": "A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Tract Infection"
      ],
      "interventions": [
        {
          "name": "RSV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1153,
      "start_date": "2019-08-07",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 145,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032093"
    },
    {
      "nct_id": "NCT02450838",
      "title": "Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "V180",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-04",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-04-04",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02450838"
    },
    {
      "nct_id": "NCT00969878",
      "title": "Multisite Controlled Trial of Cocaine Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "TA-CD Vaccination",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 300,
      "start_date": "2010-08",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00969878"
    },
    {
      "nct_id": "NCT01995617",
      "title": "Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Streptococcus Pneumoniae"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-004 Low Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-004 Low Dose + Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-004 Mid Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-004 Mid Dose + Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-004 High Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-004 High Dose + Adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genocea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 90,
      "start_date": "2013-11",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-12-11",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01995617"
    },
    {
      "nct_id": "NCT00001052",
      "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS-21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 110,
      "start_date": null,
      "completion_date": "1997-09",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-11T07:59:10.092Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001052"
    }
  ]
}